Literature DB >> 10464269

Asymmetric contributions to RNA binding by the Thr(45) residues of the MS2 coat protein dimer.

D S Peabody1, A Chakerian.   

Abstract

A prominent feature of the interaction of MS2 coat protein with RNA is the quasi-symmetric insertion of a bulged adenine (A-10) and a loop adenine (A-4) into conserved pockets on each subunit of the coat protein dimer. Because of its presence in both of these adenine-binding pockets, Thr(45) is thought to play an important role in interaction with RNA on both subunits of the dimer. To test the significance of Thr(45), we introduced all 19 amino acid substitutions. However, we were initially unable to determine the effects of the mutations on RNA binding because every substitution compromised the ability of coat protein to fold correctly. Genetic fusion of coat protein subunits reverted these protein structural defects, allowing us to show that the RNA binding activity of coat protein tolerates substitution of Thr(45), but only on one or the other subunit of the dimer. Single-chain heterodimer complementation experiments suggest that the primary site of Thr(45) interaction with RNA is with A-4 in the translational operator. Either contact of Thr(45) with A-10 makes little contribution to stability of the RNA-protein complex, or the effects of Thr(45) substitution are offset by conformational adjustments that introduce new, favorable contacts at nearby sites.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10464269     DOI: 10.1074/jbc.274.36.25403

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  10 in total

1.  Solution structure of the LicT-RNA antitermination complex: CAT clamping RAT.

Authors:  Yinshan Yang; Nathalie Declerck; Xavier Manival; Stéphane Aymerich; Michel Kochoyan
Journal:  EMBO J       Date:  2002-04-15       Impact factor: 11.598

2.  The impact of viral RNA on the association free energies of capsid protein assembly: bacteriophage MS2 as a case study.

Authors:  Karim M ElSawy
Journal:  J Mol Model       Date:  2017-02-02       Impact factor: 1.810

3.  Immunogenic display of diverse peptides on virus-like particles of RNA phage MS2.

Authors:  David S Peabody; Brett Manifold-Wheeler; Alexander Medford; Sheldon K Jordan; Jerri do Carmo Caldeira; Bryce Chackerian
Journal:  J Mol Biol       Date:  2008-04-27       Impact factor: 5.469

4.  Asymmetric interactions in the adenosine-binding pockets of the MS2 coat protein dimer.

Authors:  A J Powell; D S Peabody
Journal:  BMC Mol Biol       Date:  2001-07-25       Impact factor: 2.946

5.  Display of single-chain variable fragments on bacteriophage MS2 virus-like particles.

Authors:  Christopher A Lino; Jerri C Caldeira; David S Peabody
Journal:  J Nanobiotechnology       Date:  2017-02-13       Impact factor: 10.435

6.  Bacteriophage MS2 displays unreported capsid variability assembling T = 4 and mixed capsids.

Authors:  Natàlia de Martín Garrido; Michael A Crone; Kailash Ramlaul; Paul A Simpson; Paul S Freemont; Christopher H S Aylett
Journal:  Mol Microbiol       Date:  2019-11-05       Impact factor: 3.501

Review 7.  RNA Phage VLP-Based Vaccine Platforms.

Authors:  David S Peabody; Julianne Peabody; Steven B Bradfute; Bryce Chackerian
Journal:  Pharmaceuticals (Basel)       Date:  2021-08-04

8.  Stability and assembly in vitro of bacteriophage PP7 virus-like particles.

Authors:  Jerri C Caldeira; David S Peabody
Journal:  J Nanobiotechnology       Date:  2007-11-26       Impact factor: 10.435

9.  A Viral Platform for Chemical Modification and Multivalent Display.

Authors:  David S Peabody
Journal:  J Nanobiotechnology       Date:  2003-07-15       Impact factor: 10.435

10.  Quantitative characterization of all single amino acid variants of a viral capsid-based drug delivery vehicle.

Authors:  Emily C Hartman; Christopher M Jakobson; Andrew H Favor; Marco J Lobba; Ester Álvarez-Benedicto; Matthew B Francis; Danielle Tullman-Ercek
Journal:  Nat Commun       Date:  2018-04-11       Impact factor: 14.919

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.